Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
Summary: Patients with EGFR mutations exhibit immunosuppressive microenvironments, limiting responsiveness to immunotherapy. We used digital spatial profiling to analyze non-small cell lung carcinomas in 25 patients before and after EGFR tyrosine kinase inhibitor (TKI) treatment, including 14 patien...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | iScience |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589004224029638 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832595321989890048 |
|---|---|
| author | Soomin Kim Jaemoon Koh Tae Min Kim Songji Oh Soyeon Kim Jeonghwan Youk Miso Kim Bhumsuk Keam Yoon Kyung Jeon Dong-Wan Kim Dae Seog Heo |
| author_facet | Soomin Kim Jaemoon Koh Tae Min Kim Songji Oh Soyeon Kim Jeonghwan Youk Miso Kim Bhumsuk Keam Yoon Kyung Jeon Dong-Wan Kim Dae Seog Heo |
| author_sort | Soomin Kim |
| collection | DOAJ |
| description | Summary: Patients with EGFR mutations exhibit immunosuppressive microenvironments, limiting responsiveness to immunotherapy. We used digital spatial profiling to analyze non-small cell lung carcinomas in 25 patients before and after EGFR tyrosine kinase inhibitor (TKI) treatment, including 14 patients treated with first-line osimertinib, focusing on CD45-positive immune regions and pan-cytokeratin-positive tumor regions. Osimertinib treatment resulted in altered angiogenic pathways and immune cell proportions, with reduced plasma cells (22.2%–11.7%; p = 0.025) and increased macrophage infiltration (p = 0.145). The most predominant immune subtypes before and after treatment was the interferon-γ (IFN-γ)-dominant C2 subtype and the lymphocyte-depleted C4 subtype. Two patients who showed the opposite pattern, transiting from C4 to C2, had durable responses to subsequent atezolizumab/bevacizumab/carboplatin/paclitaxel treatment. Our results shed light on the immunomodulatory effects of osimertinib treatment and suggest that co-targeting angiogenesis and anti-programmed death (ligand) 1 might be effective in EGFR-TKI-resistant non-small cell lung cancer. |
| format | Article |
| id | doaj-art-4b9dd006e1ca47e0bf50b026cb514d63 |
| institution | Kabale University |
| issn | 2589-0042 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | iScience |
| spelling | doaj-art-4b9dd006e1ca47e0bf50b026cb514d632025-01-19T06:26:30ZengElsevieriScience2589-00422025-02-01282111736Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancerSoomin Kim0Jaemoon Koh1Tae Min Kim2Songji Oh3Soyeon Kim4Jeonghwan Youk5Miso Kim6Bhumsuk Keam7Yoon Kyung Jeon8Dong-Wan Kim9Dae Seog Heo10Cancer Research Institute, Seoul National University, Seoul, Republic of Korea; Integrated Major in Innovative Medical Science, Seoul National University College of Medicine, Seoul, Republic of KoreaDepartment of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of KoreaCancer Research Institute, Seoul National University, Seoul, Republic of Korea; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Corresponding authorCancer Research Institute, Seoul National University, Seoul, Republic of Korea; Integrated Major in Innovative Medical Science, Seoul National University College of Medicine, Seoul, Republic of KoreaCancer Research Institute, Seoul National University, Seoul, Republic of KoreaCancer Research Institute, Seoul National University, Seoul, Republic of Korea; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of KoreaCancer Research Institute, Seoul National University, Seoul, Republic of Korea; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of KoreaCancer Research Institute, Seoul National University, Seoul, Republic of Korea; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of KoreaCancer Research Institute, Seoul National University, Seoul, Republic of Korea; Integrated Major in Innovative Medical Science, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of KoreaCancer Research Institute, Seoul National University, Seoul, Republic of Korea; Integrated Major in Innovative Medical Science, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of KoreaCancer Research Institute, Seoul National University, Seoul, Republic of Korea; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of KoreaSummary: Patients with EGFR mutations exhibit immunosuppressive microenvironments, limiting responsiveness to immunotherapy. We used digital spatial profiling to analyze non-small cell lung carcinomas in 25 patients before and after EGFR tyrosine kinase inhibitor (TKI) treatment, including 14 patients treated with first-line osimertinib, focusing on CD45-positive immune regions and pan-cytokeratin-positive tumor regions. Osimertinib treatment resulted in altered angiogenic pathways and immune cell proportions, with reduced plasma cells (22.2%–11.7%; p = 0.025) and increased macrophage infiltration (p = 0.145). The most predominant immune subtypes before and after treatment was the interferon-γ (IFN-γ)-dominant C2 subtype and the lymphocyte-depleted C4 subtype. Two patients who showed the opposite pattern, transiting from C4 to C2, had durable responses to subsequent atezolizumab/bevacizumab/carboplatin/paclitaxel treatment. Our results shed light on the immunomodulatory effects of osimertinib treatment and suggest that co-targeting angiogenesis and anti-programmed death (ligand) 1 might be effective in EGFR-TKI-resistant non-small cell lung cancer.http://www.sciencedirect.com/science/article/pii/S2589004224029638therapeuticsmicroenvironmentimmune responsecancer |
| spellingShingle | Soomin Kim Jaemoon Koh Tae Min Kim Songji Oh Soyeon Kim Jeonghwan Youk Miso Kim Bhumsuk Keam Yoon Kyung Jeon Dong-Wan Kim Dae Seog Heo Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer iScience therapeutics microenvironment immune response cancer |
| title | Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer |
| title_full | Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer |
| title_fullStr | Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer |
| title_full_unstemmed | Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer |
| title_short | Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer |
| title_sort | remodeling of tumor microenvironments by egfr tyrosine kinase inhibitors in egfr mutant non small cell lung cancer |
| topic | therapeutics microenvironment immune response cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2589004224029638 |
| work_keys_str_mv | AT soominkim remodelingoftumormicroenvironmentsbyegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancer AT jaemoonkoh remodelingoftumormicroenvironmentsbyegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancer AT taeminkim remodelingoftumormicroenvironmentsbyegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancer AT songjioh remodelingoftumormicroenvironmentsbyegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancer AT soyeonkim remodelingoftumormicroenvironmentsbyegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancer AT jeonghwanyouk remodelingoftumormicroenvironmentsbyegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancer AT misokim remodelingoftumormicroenvironmentsbyegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancer AT bhumsukkeam remodelingoftumormicroenvironmentsbyegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancer AT yoonkyungjeon remodelingoftumormicroenvironmentsbyegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancer AT dongwankim remodelingoftumormicroenvironmentsbyegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancer AT daeseogheo remodelingoftumormicroenvironmentsbyegfrtyrosinekinaseinhibitorsinegfrmutantnonsmallcelllungcancer |